Key Highlights
- Viatris (NASDAQ:VTRS) fell 1.40% to USD 20.45 on November 17, about 3.5% below its 52-week high, on Volume above 100 million shares.
- Third quarter adjusted EPS climbed 6% to USD 0.71, and 2026 adjusted EPS guidance was lifted to USD 2.56 to USD 2.63 from USD 2.45 to USD 2.59.
- The company finished its USD 1.65 billion purchase of Pacira BioSciences on November 17, paying USD 36.50 per share in cash.
- The FDA cleared Ryzumvi for presbyopia on October 16, and the board declared a quarterly Dividend of USD 0.12 per share.
Third Quarter Beat on Profit and Cash Flow
Viatris posted third quarter results on November 5. Total Revenue came to USD 3.7495 billion, flat compared with the prior year, as Greater China climbed 14% to USD 702.6 million while Developed Markets slipped 2% and Emerging Markets fell 7%. Adjusted EPS was USD 0.71 against USD 0.67, adjusted EBITDA increased 4% to USD 1.1957 billion, and the adjusted gross Margin expanded to 58.0% from 56.0%. Operating Cash Flow jumped 21% to USD 899.4 million and free cash flow rose 24% to USD 813.7 million. The GAAP net loss amounted to USD 325.3 million, or USD 0.28 per share. New product revenue was about USD 115 million in the quarter, with roughly USD 450 million anticipated for the full year. Chief executive Scott A. Smith said the results reflect strong execution and support confidence in the business's growth path. Adjusted EPS for nine months reached USD 1.99, up 12%, and adjusted EBITDA for nine months grew 9% to USD 3.43 billion, so the improvement goes beyond a single quarter. Brands sales increased 1% to USD 2.46 billion, while Generics dropped 3% to USD 1.27 billion.
Guidance Raised and Pacira Completed
This marks the second guidance increase of the year. Revenue is now projected at USD 14.7 billion to USD 14.9 billion, adjusted EBITDA at USD 4.45 billion to USD 4.55 billion, adjusted EPS at USD 2.56 to USD 2.63, and free cash flow at USD 2.225 billion to USD 2.375 billion, all of which exclude any Pacira contribution. The tender offer for Pacira, announced October 8 and launched October 30, expired November 16 with about 66.5% of shares tendered. The transaction closed November 17, and management anticipates USD 90 million to USD 100 million of Pacira revenue between closing and year end. Viatris has bought back roughly USD 300 million of stock this year and still has about USD 700 million of authorization available, and the USD 0.12 dividend is payable December 16 to holders of record as of November 23. The tender was financed in cash and needed no Pacira Shareholder vote, which kept the timeline short. Pacira shares were removed from Nasdaq following completion.
Supply Issues and Near-Term Catalysts
Supply constraints shaved about USD 100 million from third quarter revenue, and a comparable impact is expected in the fourth quarter. In October the company voluntarily halted operations at its Nashik Facility in India after the FDA designated it Official Action Indicated, and output is expected to restart in the first quarter of 2027. Additional catalysts include the launch of Gwyn Lo, the approval of Wakix in Japan and an FDA goal date of December 27 for fast acting meloxicam. A multiyear Partnership with the Cadillac Formula 1 team was revealed November 16. Net Debt remains significant, with total debt around USD 13.3 billion, so integration and deleveraging after the Pacira purchase will get close attention. Since Pacira's contribution is left out of guidance, any gain from the deal would be additional to these ranges, while integration costs will show up in the fourth quarter.
Where Things Stand
Viatris lifted guidance, closed a major Acquisition and won a new approval within just a few weeks. The December meloxicam decision and the Nashik restart are the next milestones. Canadian investors in generic drug names will watch the same Supply risks.






Please wait processing your request...